Hepatology 2010, 52:1731–1740.PubMedCrossRef 15. Jiang F, Liu T, He Y, Yan Q, Chen X, Wang H, Wan X: MiR-125b ACY-1215 cell line promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. BMC Cancer 2011, 11:425.PubMedCrossRef 16. Tang F, Zhang R, He Y, Zou M, Guo L, Xi T: MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells. PLoS One 2012,

7:e35435.PubMedCrossRef 17. Kappelmann M, Kuphal S, Meister G, Vardimon L, Bosserhoff AK: MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression. Oncogene 2012. [Epub ahead of print] SAHA HDAC manufacturer 18. Ngo-Yin Fan D, Ho-Ching

Tsang F, Hoi-Kam Tam A, Leung-Kuen Au S, Chak-Lui Wong C, Wei L, Man-Fong Lee J, He X, Oi-Lin Ng I, Wong CM: Histone lysine methyltransferase, suppressor of variegation 3–9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b. Hepatology 2013,57(2):637–47.CrossRef 19. Xu N, Zhang L, Meisgen F, Harada M, Heilborn J, Homey B, Grandér D, Ståhle M, Sonkoly E, Pivarcsi A: MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion. J Biol Chem 2012,287(35):29899–908.PubMedCrossRef Temsirolimus manufacturer 20. Liu LH, Li H, Li JP, Zhong H, Zhang HC, Chen J: Xiao T.miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. Biochem Biophys Res Commun 2011,416(1–2):31–8.PubMedCrossRef 21. Martin ES, Cesari R, Pentimalli F, Yoder K, Fishel R, Himelstein AL, Martin SE, Godwin AK, Negrini M, Croce CM: The BCSC-1 locus at chromosome 11q23-q24 is a candidate

tumor suppressor gene. Proc Natl Acad Sci USA 2003,100(20):11517–22.PubMedCrossRef 22. Cui EH, Li HJ, Hua F, Wang B, Mao W, Feng XR, Li JY, Wang X: Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. Acta Pharmacol Sin 2013,34(2):309–13.PubMedCrossRef 23. Yuxia M, Zhennan T, Wei Z: Circulating miR-125b is a novel biomarker for screening non-small-cell Vasopressin Receptor lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol 2012,138(12):2045–50.PubMedCrossRef 24. Lin KY, Zhang XJ, Feng DD, Zhang H, Zeng CW, Han BW, Zhou AD, Qu LH, Xu L, Chen YQ: miR-125b, a target of CDX2, regulates cell differentiation through repression of the core binding factor in hematopoietic malignancies. J Biol Chem 2011,286(44):38253–63.PubMedCrossRef 25. Toh Y, Kuninaka S, Endo K, Oshiro T, Ikeda Y, Nakashima H, Baba H, Kohnoe S, Okamura T, Nicolson GL, Sugimachi K: Molecular analysis of a candidate metastasis-associated gene, MTA1: possible interaction with histone deacetylase 1. J Exp Clin Cancer Res 2000, 19:105–11.